Literature DB >> 23065390

Novel therapeutic approaches to preserve the right ventricle.

Samar Farha1, Erika L Lundgrin, Serpil C Erzurum.   

Abstract

The right ventricle (RV) is increasingly recognized for its role in heart disease. In fact, RV function is a strong predictor of outcome in patients with cardiovascular disease. Although the focus in heart failure has been on the left ventricle (LV), recently the spotlight has been shifting to include the RV. The RV and LV have different embryological origins and respond differently to stressors and to therapies. Newer therapies targeting the RV have been investigated in an attempt to improve right-ventricular adaptation to cardiovascular diseases. In this review, we summarize the differences between the RV and LV and focus on novel therapies that target the RV.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23065390      PMCID: PMC3575635          DOI: 10.1007/s11897-012-0119-3

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  51 in total

Review 1.  Right ventricular adaptation and maladaptation in chronic pulmonary arterial hypertension.

Authors:  Stuart Rich
Journal:  Cardiol Clin       Date:  2012-05       Impact factor: 2.213

2.  Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension.

Authors:  Serge A van Wolferen; Johannes T Marcus; Anco Boonstra; Koen M J Marques; Jean G F Bronzwaer; Marieke D Spreeuwenberg; Pieter E Postmus; Anton Vonk-Noordegraaf
Journal:  Eur Heart J       Date:  2007-01-22       Impact factor: 29.983

3.  Tricuspid annular displacement predicts survival in pulmonary hypertension.

Authors:  Paul R Forfia; Micah R Fisher; Stephen C Mathai; Traci Housten-Harris; Anna R Hemnes; Barry A Borlaug; Elzbieta Chamera; Mary C Corretti; Hunter C Champion; Theodore P Abraham; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2006-08-03       Impact factor: 21.405

4.  Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway.

Authors:  J L Rouleau; G Kapuku; S Pelletier; H Gosselin; A Adam; C Gagnon; C Lambert; S Meloche
Journal:  Circulation       Date:  2001-08-21       Impact factor: 29.690

5.  Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension.

Authors:  Soban Umar; Yvonne P de Visser; Paul Steendijk; Cindy I Schutte; El Houari Laghmani; Gerry T M Wagenaar; Wilhelmina H Bax; Eleni Mantikou; Daniel A Pijnappels; Douwe E Atsma; Martin J Schalij; Ernst E van der Wall; Arnoud van der Laarse
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-25       Impact factor: 4.733

Review 6.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

Review 7.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Authors:  J N Cohn; R Ferrari; N Sharpe
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

8.  Enalapril improves heart failure induced by monocrotaline without reducing pulmonary hypertension in rats: roles of preserved myocardial creatine kinase and lactate dehydrogenase isoenzymes.

Authors:  K Ishikawa; H Hashimoto; S Mitani; Y Toki; K Okumura; T Ito
Journal:  Int J Cardiol       Date:  1995-01-06       Impact factor: 4.164

9.  A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted.

Authors:  Jayan Nagendran; Vikram Gurtu; David Z Fu; Jason R B Dyck; Al Haromy; David B Ross; Ivan M Rebeyka; Evangelos D Michelakis
Journal:  J Thorac Cardiovasc Surg       Date:  2008-05-23       Impact factor: 5.209

10.  Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats.

Authors:  Muneyoshi Okada; Toshiyuki Harada; Ryuta Kikuzuki; Hideyuki Yamawaki; Yukio Hara
Journal:  J Pharmacol Sci       Date:  2009-10-06       Impact factor: 3.337

View more
  5 in total

1.  The first annual Drug Discovery and Development Symposium for Pulmonary Hypertension.

Authors:  John H Newman
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

2.  Regulation and function of miR-214 in pulmonary arterial hypertension.

Authors:  Hannah C Stevens; Lin Deng; Jennifer S Grant; Karine Pinel; Matthew Thomas; Nicholas W Morrell; Margaret R MacLean; Andrew H Baker; Laura Denby
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

3.  Influence of Right Ventricular Dysfunction on Outcomes of Left Ventricular Non-compaction Cardiomyopathy.

Authors:  Wuwan Wang; Wei Chen; Xue Lin; Ligang Fang
Journal:  Front Cardiovasc Med       Date:  2022-01-31

4.  Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension.

Authors:  Rhoda E Kuc; Myrna Carlebur; Janet J Maguire; Peiran Yang; Lu Long; Mark Toshner; Nicholas W Morrell; Anthony P Davenport
Journal:  Life Sci       Date:  2014-02-26       Impact factor: 5.037

Review 5.  Right ventricular phenotype, function, and failure: a journey from evolution to clinics.

Authors:  Yannick J H J Taverne; Amir Sadeghi; Beatrijs Bartelds; Ad J J C Bogers; Daphne Merkus
Journal:  Heart Fail Rev       Date:  2021-11       Impact factor: 4.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.